©1996 by The American Society for Biochemistry and Molecular Biology, Inc.
Purification of an RNA Polymerase II Transcript Release Factor from Drosophila(*)

(Received for publication, December 14, 1995; and in revised form, February 14, 1996)

Zhi Xie David H. Price

From the Department of Biochemistry, University of Iowa, Iowa City, Iowa 52242

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
REFERENCES

ABSTRACT

Factor 2 was previously identified in Drosophila K(c) cell nuclear extract (K(c)N) as an activity suppressing the appearance of long transcripts (Price, D. H., Sluder, A. E., and Greenleaf, A. L.(1987) J. Biol. Chem. 262, 3244-3255). A 154-kDa protein with factor 2 activity was purified to apparent homogeneity from K(c)N. An immobilized template assay indicated that factor 2 caused the release of transcripts by RNA polymerase II in an ATP-dependent manner. Some early elongation complexes were resistant to factor 2 action but became sensitive after treatment with 1 M KCl. In the absence of factor 2, transcription complexes still exhibited a low degree of processivity suggesting that factor 2 was only partially responsible for abortive elongation.


INTRODUCTION

The study of eucaryotic gene expression is aided by the application of procaryotic paradigms. A major feature of procaryotic transcriptional control is the default employment of negative elongation potential, which stops RNA polymerase before a gene is fully transcribed. Control of expression is accomplished through the action of positive factors, which alleviate pausing or termination so that full-length mRNAs are synthesized. Attenuation of the tryptophan operon in Escherichia coli and anti-termination by bacteriophage N and Q proteins are two examples in procaryotes in which expression of operons is regulated by specific blocks to transcription elongation(1) . Although there are intrinsic signals for pausing and termination, specific termination factors also play an important role in the control process. E. coli Rho protein is the most extensively studied termination factor(2, 3) . It binds the nascent RNA, uses ATP to drive translocation along the transcript toward the elongation complex, and then causes the dissociation of the RNA from the ternary complex. The interplay of negative and positive factors provides the means to control transcription elongation.

As is found in procaryotes the control of transcription elongation is also critical for gene expression in eucaryotes(4, 5, 6) . Factor-dependent termination has been observed for eucaryotic RNA polymerases. A specific sequence in the nascent transcript is not sufficient to terminate vaccinia RNA polymerase but requires a viral termination factor identical with vaccinia mRNA capping enzyme(7) . In the transcription systems directed by RNA polymerase I (8, 9) or RNA polymerase III (10) or mitochondrial polymerase(11, 12) , specific termination factors have also been described. No RNA polymerase II termination factor has been identified.

We proposed a model for the control of elongation by Drosophila RNA polymerase II that incorporated the function of both negative and positive factors(13, 14) . The model states that all RNA polymerase II molecules that initiate from a promoter are destined to produce only short transcripts due to the action of negative transcription elongation factors (N-TEF). (^1)Escape from this abortive elongation into productive elongation requires the action of positive transcription elongation factors (P-TEF). Fractionation studies have recently identified three components required to efficiently generate productive elongation complexes(15) . One of these components, P-TEFb, was purified to apparent homogeneity and was shown to act after initiation(15) . N-TEF was proposed to function early during transcription and result in pausing and premature termination(14) . Here we report the purification of factor 2, a component of N-TEF, from Drosophila K(c) cells.


EXPERIMENTAL PROCEDURES

Chromatography and Fractionation

General chromatography procedures were as described by Price et al.(16) . All columns were run in HGKEDP (25 mM HEPES, pH 7.6, 15% glycerol, indicated molar concentration of KCl, 0.1 mM EDTA, 1 mM dithiothreitol, and 0.1% of a saturated solution of phenylmethylsulfonyl fluoride in isopropyl alcohol) except ceramic hydroxyapatite column (Bio-Rad CHT10), for which potassium phosphate (pH 7.6) was used instead of KCl in HGKEDP (HGPEDP). Fractionation of K(c)N was carried out according to the step procedure described earlier(15) .

Purification of Factor 2

Factor 2 was purified from Drosophila K(c)N using an in vitro transcription assay (see below). 124 ml of nuclear extract was loaded on a 500-ml P-11 column at 125 mM HKEDP. Proteins eluting between 0.1 and 0.3 M KCl were dialyzed against HGEDP until the salt was 100 mM KCl and then loaded on a 250-ml DE52 column. Proteins bound to DE52 were eluted with a 100 to 600 mM KCl gradient. Factor 2 eluted from 180 to 220 mM KCl, and these fractions were pooled and directly loaded on a 10-ml ceramic hydroxyapatite column equilibrated with 50 mM HGPEDP. The material bound to the hydroxyapatite column was eluted with a 50-500 mM phosphate gradient. The fractions (220-350 mM phosphate) containing factor 2 activity were pooled and dialyzed versus HGEDP until the phosphate concentration was 100 mM and then loaded on a 1-ml Mono S column. The material bound to the Mono S column was eluted with a 110-600 mM KCl gradient. Factor 2 eluted from 150 to 170 mM KCl and was pooled and loaded on a 1-ml Mono Q column equilibrated at 160 mM KCl. The material bound to Mono Q was eluted with a 160-700 mM KCl gradient, and factor 2 eluted from 320 to 340 mM KCl. A 500-µl sample from Mono Q fraction 36 (peak fraction of factor 2) was loaded on a 4.5-ml 20-35% glycerol gradient and centrifuged at 55,000 rpm (287,000 times g) in a Beckman SW 55Ti rotor at 1 °C for 38 h.

In Vitro Transcription

A continuous labeling protocol (16) was used to assay the effect of factor 2 on transcription. Reactions contained the following: 20 mM HEPES, 5 mM MgCl(2), 600 µM of each ATP, GTP, UTP, 30 µM CTP, 60 mM KCl, 3 µCi of [alpha-P]CTP, 6 µg/ml DNA template, and partially purified factors that supported transcription initiation and elongation. The template was actin Act5C(13) , linearized with either SalI or HpaI giving a 1,000- or 520-nucleotide runoff, respectively. A mixture of partially purified factors included 0.2 µl of DNase inhibitor, 0.2 µl of RNA polymerase II, 0.2 µl of TFIIE (Drosophila factor 3), and 1.1 µl of concentrated P-11-0.4 M step. The reactions were started by adding a transcription mixture containing the buffer, MgCl(2), NTPs, and template. 12.5-µl reactions were incubated at 25 °C for 20 min. The reactions were stopped and the labeled transcripts were isolated and analyzed by denaturing gels(16) .

Transcript Release Assay

The immobilized actin template was synthesized as described earlier(14) . Transcription of the HpaII cut template generated a 780-nucleotide runoff. The template was first incubated with K(c)N in the presence of 20 mM HEPES and 5 mM MgCl(2) for 10 min at 25 °C to form preinitiation complexes. The preinitiation complexes were then pulse-labeled for 15 or 20 s to generate early elongation complexes. The pulse solution contained 5 µCi of [alpha-P]CTP and brought the reaction mixture to 600 µM GTP, ATP, and UTP. The reaction was stopped by adding EDTA to a final concentration of 10 mM. The resulting early elongation complexes were concentrated magnetically and washed four times with HMK buffer, which contained 20 mM HEPES, 5 mM MgCl(2), and either 60 mM, 250 mM, or 1 M KCl as described in the text. High salt washed complexes were washed another three times with low salt buffer. The washed early elongation complexes were resuspended in 60 mM HMK buffer and aliquoted to individual reaction tubes (8 µl in each). After addition of 4 µl of a mixture containing 60 mM HMK and the indicated concentration of ATP or factor 2, or both, the washed complexes were incubated at 25 °C for 5 min. The reactions were stopped with 18 µl of HKE (20 mM HEPES, 60 mM KCl, and 10 mM EDTA). The beads were concentrated, and the supernatant containing released transcripts was removed. Labeled transcripts in supernatant and bead fractions were isolated and analyzed on 18% denaturing gels(16) . Labeled transcripts were quantitated using a Packard InstantImager.

To test the effect of factor 2 on washed early elongation complexes during transcription (see Fig. 4), a chase solution was added to allow further elongation in the presence or absence of factor 2. The chase solution brought the reaction to either 60 or 250 mM HMK and 600 µM GTP, ATP, CTP, and UTP. The reactions were stopped with HKE. The labeled transcripts in soluble and bead fractions were isolated and analyzed in 6% denaturing gels(16) .


Figure 4: Function of factor 2 during elongation. Early elongation complexes were generated, washed with either 60 mM KCl (A) or 1 M KCl (B) containing buffers and chased as described under ``Experimental Procedures'' and diagrammed. The transcripts were analyzed with 6% polyacrylamide gel electrophoresis. washed complexes, washed early elongation complexes before the chase. Factor 2 (F2), 0.3 µl (A) or 0.1 and 0.3 µl (B) of glycerol gradient fraction 13 (see Fig. 2), was added as indicated during the chase. B, bound; S, supernatant; nt, nucleotide.




Figure 2: Purification of factor 2. A and D, silver-stained 6-15% gradient SDS protein gel analysis of the indicated fractions generated during the last two steps of purification. B and E, transcriptional analysis for suppression activity as in Fig. 1A except that a template with a 520-nucleotide (nt) runoff was used. C and F, immobilized template assay for transcript release activity as in Fig. 1B except that complexes were washed with 1 M KCl, and 600 µM ATP was used. Only the released transcript fraction was analyzed. -, no addition of factor 2; OP, onput fraction; M, 10-kDa ladder protein marker.




Figure 1: Negative transcription activity of partially purified factor 2. A, titration of factor 2 during in vitro transcription using a continuous labeling protocol detailed under ``Experimental Procedures.'' Increasing volumes of partially purified factor 2 (0.05, 0.1, 0.2, 0.4, 0.8, and 1.6 µl) were added. -, no addition; +, addition of 1 µl of partially purified factor 2. Transcripts were analyzed by denaturing 6% polyacrylamide gel electrophoresis. The position of a 1,000-nucleotide runoff is indicated. B, immobilized template assay for transcript release activity. Isolated early elongation complexes were generated by pulse labeling followed by 250 mM KCl wash as described under ``Experimental Procedures'' and diagrammed above the gel. 150 µM ATP was used in the transcript release assay. Released transcripts in the supernatant (S) and bound transcripts associated with the immobilized template (B) were separated and analyzed by denaturing 18% polyacrylamide gel electrophoresis. nt, nucleotides.




RESULTS

Elongation control involves the action of both positive and negative factors(13, 14) . Recently we showed that partially purified Drosophila factor 2 was involved in this process(15) . To further define the role of factor 2 we undertook its purification. We used a set of partially purified factors that reconstructs accurate initiation from a promoter-containing template (15, 16) but does not support the production of DRB-sensitive transcripts because of the lack of P-TEFb(15) . Using this system factor 2 suppressed the appearance of long transcripts(16) .

Partially Purified Factor 2 Contains a Transcript Release Activity

We examined the properties of factor 2 at an intermediate stage in its purification. A third column fraction (Mono Q, see ``Experimental Procedures'') was titrated into reconstruction reactions lacking P-TEFb. As the amount of factor 2 increased the appearance of long transcripts was suppressed (Fig. 1A). To exclude the possibility of ribonuclease contamination, a transcription reaction was carried out without factor 2 and then stopped with alpha-amanitin. The reaction was then incubated with or without partially purified factor 2 for another 10 min. No change was observed in the pattern of transcripts indicating that the crude factor 2 fraction was not contaminated with ribonuclease (Fig. 1A, last two lanes).

Since factor 2 suppressed the generation of long transcripts, increased pausing or termination was a possible explanation. An immobilized DNA template was used to differentiate paused from terminated transcripts. Early elongation complexes were isolated and then incubated with partially purified factor 2 in the presence or absence of ATP. Released RNAs were separated from the template-associated transcripts by magnetic concentration. Factor 2 or ATP by itself was not sufficient to release the transcripts associated with early elongation complexes (Fig. 1B). However, in the presence of ATP, partially purified factor 2 caused the release of transcripts associated with the immobilized complexes (Fig. 1B).

Factor 2 Is a 154-kDa Monomer

To further characterize the factor we used the continuous labeling transcription assay and the transcript release assay to purify factor 2. After multiple steps (see ``Experimental Procedures''), factor 2 was purified to near homogeneity. Analysis of the fifth and sixth purification steps, Mono Q chromatography and glycerol gradient sedimentation, showed that a 154-kDa protein correlated with factor 2 activity in both assays (Fig. 2). Comparison of the sedimentation of factor 2 to known proteins suggested that factor 2 was a monomer (data not shown).

Factor 2 Associates with Elongation Complexes

Early elongation complexes washed with either 60 mM or 1 M HMK were tested for their dependence on ATP or factor 2 to release nascent transcripts (Fig. 3A). The low salt washed complexes released 40% of the associated transcripts when only ATP was added, and further supplementation of factor 2 had little effect (Fig. 3A). This transcript release activity could be due to associated factor 2 or another ATP-dependent transcript release factor. Complexes washed with 1 M HMK were not able to release nascent transcripts when only ATP was added. Therefore, the ATP-dependent transcript release activity associated with low salt washed complexes was removed by the high salt wash. However, when factor 2 was supplemented in the presence of ATP, 70% of the RNAs associated with high salt washed complexes was released (Fig. 3A). It is possible that the high salt wash removed protein(s) that inhibit transcript release. A comparison of the pattern of transcripts released indicated that there was a slight preference for retention of longer transcripts (over 19 nucleotides) by low salt washed complexes while transcripts of all sizes were equally released from high salt washed complexes. This difference may be due to heterogeneity of the low salt washed complexes. If there was an inhibitor of transcript release, it might preferentially associate with complexes containing longer transcripts.


Figure 3: Association of factor 2 with elongation complexes. A, early elongation complexes were generated and washed with either low (60 mM KCl) or high salt (1 M KCl) as described under ``Experimental Procedures'' and diagrammed above the gel. 600 µM ATP was used in the termination assay. Either the total or the released transcripts were analyzed as indicated on an 18% polyacrylamide gel. Total transcripts were analyzed after washing and represent the starting material for the termination reactions. nt, nucleotides. B, interaction of factor 2 with high salt washed early elongation complexes. High salt (1 M KCl) washed early elongation complexes were generated as described in A and incubated with purified factor 2 for 2 min at 25 °C. After the incubation, the complexes were washed with low or high salt and analyzed as described in A.



Factor 2 promoted transcript release from high salt washed complexes, but it was not clear if it associated with these complexes. To address this question, high salt washed early elongation complexes were generated and incubated with factor 2 without ATP. After washing again with low salt, these complexes were able to release 60% of the associated transcripts when only ATP was added. This indicated that factor 2 stably associated with the elongation complexes under low salt conditions. Supplementation with additional factor 2 caused a slight increase in the percentage of transcripts released (Fig. 3B). This additional release could have been due to a subsaturating level of factor 2 being used in the first incubation. After washing again with 1 M KCl, most of the transcript release activity was removed, indicating that the association of factor 2 with elongation complexes was not stable to high salt (Fig. 3B). Supplementation of factor 2 restored the transcript release activity. These association studies indicated that the properties of factor 2 were similar to those of the transcript release activity found in the initial low salt washed complexes (Fig. 3A). The simplest explanation is that factor 2 is responsible for all transcript release we observed. Once antibodies to factor 2 are available, it will be possible to determine if factor 2 is present in the initial elongation complexes.

Factor 2 Promotes the Release of RNAs from Transcription Complexes during Elongation

All of the transcript release experiments shown so far utilized elongation complexes stalled by depleting the NTPs. The continuous labeling experiments (Fig. 2, B and E) indicated that factor 2 functioned during elongation. To determine if factor 2 could cause the release of transcripts during elongation, we examined the effect of factor 2 on isolated complexes supplemented with NTPs. As was found with stalled complexes, 40% of the associated transcripts were released during elongation by low salt washed complexes (Fig. 4A). Similarly, more than 50% of the transcripts were resistant to release during elongation, even when supplemented with factor 2. These results suggested that the hypothesized inhibitor of transcript release did not dissociate during elongation. Even though the resistant complexes remained competent to elongate in the presence of high salt, elongation under low salt was limited. This suggested that some component of N-TEF was present (Fig. 4A).

As expected, high salt washed early elongation complexes did not release transcripts during subsequent elongation in 60 mM KCl. Surprisingly, these complexes still encountered blocks to elongation (Fig. 4B). These blocks were substantially relieved by chasing with 250 mM KCl. Evidently, some component of N-TEF seen in low salt washed resistant complexes was retained after the high salt wash. This component of N-TEF was apparently suppressed but not removed by treatment with high salt. When the high salt washed complexes were supplemented with increasing amounts of factor 2, there was a decrease in the length of the transcripts synthesized and an increase in the amount of released transcripts (Fig. 4B). As was seen with the stalled complexes, almost all of the complexes became substrates for factor 2 after high salt treatment.


DISCUSSION

We purified Drosophila factor 2 and determined that it caused the release of the RNA component of RNA polymerase II elongation complexes in an ATP-dependent manner. We refer to factor 2 as a transcript release factor rather than a termination factor only because we have not determined if the polymerase is also released from the template. Since it is not likely that the polymerase continues to synthesize RNA after the transcript is released, it is probable that factor 2 acts as a true termination factor.

Factor 2 is involved in abortive elongation but is not completely responsible for the process. Abortive elongation is characterized by the rapid generation of short transcripts due to pausing of the polymerase followed by termination of some of the transcripts(13, 14) . Although factor 2 plays a role in transcript release, two of our results indicate that other factors also contribute to abortive elongation. First, the low salt washed complexes that were resistant to factor 2 were unable to synthesize long transcripts at 60 mM KCl even though the transcripts remained in elongation complexes (Fig. 4A). Second, complexes washed by high salt, though lacking factor 2, still synthesized shorter transcripts on average at 60 mM KCl compared with 250 mM KCl (Fig. 4B). It appeared that some of the abortive properties of the elongation complexes could be suppressed but not removed by high salt. Our earlier results (13, 14) and those presented here suggest that preinitiation complexes confer a negative elongation potential on the early elongation complexes. This could be due to a factor in preinitiation complexes, which remains in elongation complexes, or to the action of a factor on some component of elongation complexes, perhaps through a covalent modification.

Our results indicate that a fraction of early elongation complexes was resistant to transcript release. This was demonstrated by the inability of added factor 2 to cause additional transcript release from low salt washed complexes. If the salt remained low, the inhibitor remained associated with the complexes during elongation. The lack of function of factor 2 on isolated early elongation complexes (Fig. 3A) seemed to contradict the clear effect of added factor 2 in the continuous labeling transcription experiments using crude fractions (Fig. 2, B and E). This apparent discrepancy arose because the two assay systems were quite different. In the transcript release assay the effect of factor 2 was examined on washed elongation complexes, while in the continuous labeling assay the effect of factor 2 was tested in the presence of crude fractions without washing. Factors, including known elongation factors, in the continuous labeling assay might have influenced the activity of factor 2 or the inhibitor, and these factors would have been removed by the low salt wash. Elucidation of the properties of the inhibitor and identification of other factors that may be involved will be necessary to completely understand the function of factor 2 in elongation control.

The inhibitor of factor 2 function could be a nonspecific protein that blocks the association of factor 2 or could be a specific factor restricting the activity of factor 2 to a certain type of elongation complex. Partially purified factor 2 was shown to stimulate productive elongation by P-TEFb(15) . Preliminary results with pure factor 2 suggest the stimulatory effect was probably due to contaminating factors in the fraction (data not shown). In reactions containing the factors required for the generation of DRB-sensitive long runoff transcripts, the crude factor 2 fraction used did not inhibit the appearance of long transcripts(15) , suggesting that factor 2 selectively acted on a subset of elongation complexes. One intriguing possibility is that the inhibitor protects a subset of elongation complexes from factor 2 action and that these complexes are then acted upon by P-TEF to allow the transition into productive elongation. Alternatively, it is possible that only the complexes that factor 2 can act on are potentially productive. If this is the case, P-TEF would have to act before factor 2 caused transcript release. These opposing models could be tested by determining if P-TEF can act on the factor 2-resistant complexes.

The mechanism of factor 2 action may share some similarities with other termination factors. Factor 2 is like the E. coli rho factor and vaccinia capping enzyme in that it requires ATP for function(7, 17) . Unlike rho, however, factor 2 can associate with early elongation complexes containing RNA less than 10 nucleotides in length and cause transcript release. Such short transcripts are probably still sequestered within RNA polymerase II (18, 19) and are not accessible to RNA binding proteins. The tight interaction of factor 2 with early elongation complexes is more likely through DNA, RNA polymerase II itself, or other associated factors. A transcription/repair coupling factor (TRCF) has been identified in E. coli, which increases the rate of repair of transcribed regions(20, 21) . TRCF recognizes stalled elongation complexes caused by DNA lesions, nucleotide starvation, or protein roadblocks and dissociates the ternary complexes upon ATP hydrolysis. TRCF contains an RNA polymerase binding motif and binds double strand DNA but has little affinity for RNA. There is a possibility that factor 2 may be the eucaryotic homologue of E. coli TRCF, but protein sequence and detailed functional studies are needed to justify this hypothesis.


FOOTNOTES

*
This work was supported by National Institutes of Health Grant RO1-GM35500. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

(^1)
The abbreviations used are: N-TEF, negative transcription elongation factor(s); P-TEF, positive transcription elongation factor(s); TRCF, transcription/repair coupling factor; DRB, 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole.


REFERENCES

  1. Platt, T. (1986) Annu. Rev. Biochem. 55, 339-372 [CrossRef][Medline] [Order article via Infotrieve]
  2. Yager, T. D., and von Hippel, P. H. (1987) in Escherichia coli and Salmonella typhimurium (Neidhardt, F. C., Ingraham, J. L., Low, K. B., Magasanik, B., Schaechter, M., and Umbarger, H. E., eds) pp. 1241-1275, American Society for Microbiology, Washington, D. C.
  3. Richardson, J. P. (1990) Biochim. Biophys. Acta 1048, 127-138 [Medline] [Order article via Infotrieve]
  4. Wright, S. (1993) Mol. Biol. Cell 4, 661-668 [Medline] [Order article via Infotrieve]
  5. Kerppola, T. K., and Kane, C. M. (1991) FASEB J. 5, 2833-2842 [Abstract/Free Full Text]
  6. Spencer, C. A., and Groudine, M. (1990) Oncogene 5, 777-786 [Medline] [Order article via Infotrieve]
  7. Hagler, J., Luo, Y., and Shuman, S. (1994) J. Biol. Chem. 269, 10050-10060 [Abstract/Free Full Text]
  8. Kuhn, A., Bartsch, I., and Grummt, I. (1990) Nature 344, 559-562 [CrossRef][Medline] [Order article via Infotrieve]
  9. Bartsch, I., Schoneberg, C., and Grummt, I. (1988) Mol. Cell. Biol. 8, 3891-3897 [Medline] [Order article via Infotrieve]
  10. Gottlieb, E., and Steitz, J. A. (1989) EMBO J. 8, 851-861 [Abstract]
  11. Daga, A., Micol, V., Hess, D., Aebersold, R., and Attardi, G. (1993) J. Biol. Chem. 268, 8123-8130 [Abstract/Free Full Text]
  12. Kruse, B., Narasimhan, N., and Attardi, G. (1989) Cell 58, 391-397 [Medline] [Order article via Infotrieve]
  13. Kephart, D. D., Marshall, N. F., and Price, D. H. (1992) Mol. Cell. Biol. 12, 2067-2077 [Abstract]
  14. Marshall, N. F., and Price, D. H. (1992) Mol. Cell. Biol. 12, 2078-2090 [Abstract]
  15. Marshall, N. F., and Price, D. H. (1995) J. Biol. Chem. 270, 12335-12338 [Abstract/Free Full Text]
  16. Price, D. H., Sluder, A. E., and Greenleaf, A. L. (1987) J. Biol. Chem. 262, 3244-3255 [Abstract/Free Full Text]
  17. Richardson, J., and Conaway, R. (1980) Biochemistry 19, 4293-4299 [Medline] [Order article via Infotrieve]
  18. Sluder, A. E., Price, D. H., and Greenleaf, A. L. (1988) J. Biol. Chem. 263, 9917-9925 [Abstract/Free Full Text]
  19. Coppola, J. A., Field, A. S., and Luse, D. S. (1983) Proc. Natl. Acad. Sci. U. S. A. 80, 1251-1255 [Abstract]
  20. Selby, C. P., and Sancar, A. (1995) J. Biol. Chem. 270, 4882-4889 [Abstract/Free Full Text]
  21. Selby, C. P., and Sancar, A. (1995) J. Biol. Chem. 270, 4890-4895 [Abstract/Free Full Text]

©1996 by The American Society for Biochemistry and Molecular Biology, Inc.